222551-17-9
基本信息
1-(2,3-二氫-1,4-苯并二惡烷-5-基)-4-[[5-(4-氟苯基)-3-吡啶基]甲基]哌嗪
SLV 313
adoprazine
Unii-7snb18Q89d
Adoprazine (SLV313)
SLV 313
SLV313
SLV-313
1-(2,3-Dihydro-1,4-benzodioxin-5-yl)-4-[[5-(4-fluorophenyl)-3-pyridinyl]methyl]piperazine
Piperazine, 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-[[5-(4-fluorophenyl)-3-pyridinyl]methyl]-
物理化學(xué)性質(zhì)
報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
2024/11/08 | HY-14782 | 1-(2,3-二氫-1,4-苯并二惡烷-5-基)-4-[[5-(4-氟苯基)-3-吡啶基]甲基]哌嗪 Adoprazine | 222551-17-9 | 5mg | 1400元 |
2024/11/08 | HY-14782 | 1-(2,3-二氫-1,4-苯并二惡烷-5-基)-4-[[5-(4-氟苯基)-3-吡啶基]甲基]哌嗪 Adoprazine | 222551-17-9 | 10mM * 1mLin DMSO | 1540元 |
2024/11/08 | HY-14782 | 1-(2,3-二氫-1,4-苯并二惡烷-5-基)-4-[[5-(4-氟苯基)-3-吡啶基]甲基]哌嗪 Adoprazine | 222551-17-9 | 10mg | 2200元 |
常見問題列表
5-HT 1A Receptor 9 (pEC 50 ) |
D 2 Receptor 9.3 (pA2) |
D 3 Receptor 8.9 (pA2) |
D 4 Receptor 8.0 (pKi) |
5-HT 7 Receptor 7.2 (pKi) |
5-HT 1A Receptor 9.1 (pKi) |
D 2 Receptor 8.4 (pKi) |
D 3 Receptor 8.4 (pKi) |
Adoprazine (SLV313) has high affinity at human recombinant D 2 , D 3 , D 4 , 5-HT 2B , and 5-HT 1A receptors, with pK i s of 8.4, 8.4, 8.0, 7.9 and 9.1, respectively. Adoprazine (SLV313) acts as a high potency dopamine D 2 receptor antagonist and an efficacious serotonin 5-HT 1A receptor agonist, with E max value (% effect of 10 μM 5-HT) of 73 and pK B value of 8.5 .
Adoprazine (SLV313) (0.1-10 mg/kg; p.o.; single) is sufficient to reduce extracellular 5-HT and increase dopamine levels in the nucleus accumbens in a dose- and time-dependent manner.
Animal Model: | Male Wistar rats (275-350 g) |
Dosage: | 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg |
Administration: | p.o.; single |
Result: | Led to a dose- and time-dependent increase in extracellular levels of DA, DOPAC, and HVA. In contrast, led to a reduction in 5-HT levels and no change in 5-HIAA levels. |